基线MRI客观炎症预测早期预后不良类风湿关节炎的治疗获益
AVERT研究事后分析纳入早期抗CCP阳性MTX未治RA患者,按基线手腕MRI滑膜炎和骨炎截断值分为高/低炎症组。高炎症组中阿巴西普联合MTX较MTX单药显著提高12个月缓解率,低炎症组无显著差异。
要点
- 高基线MRI炎症患者中,阿巴西普联合MTX的SDAI缓解率45.1% vs MTX 16.3%(P=0.0022)。
- 低基线MRI炎症患者中,两治疗组SDAI缓解率无显著差异(39.7% vs 32.3%,P=0.4961)。
- 基线MRI客观高炎症可识别从阿巴西普联合MTX治疗中获益的早期RA患者。
核心结论
- 在血清阳性、MTX未治的早期RA患者中,基线MRI客观高炎症提示预后不良,阿巴西普联合MTX较MTX单药获得更高缓解率。
研究设计与样本
- AVERT为IIIb期随机对照试验,12个月双盲治疗期,纳入病程≤2年、抗CCP阳性、MTX未治的早期RA患者。
- 本事后分析纳入阿巴西普联合MTX组(n=114)和MTX组(n=111)中有MRI结果的患者,按既往建立的单侧手腕增强MRI滑膜炎和骨炎截断值分为低与高基线炎症组。
主要发现
- 225例中100例(44.4%)有高基线MRI炎症。
- 高基线MRI炎症患者中,阿巴西普联合MTX组12个月SDAI缓解率45.1% vs MTX组16.3%(P=0.0022)。
- 高基线MRI炎症患者中,CDAI缓解率47.1% vs 20.4%(P=0.0065),Boolean缓解率39.2% vs 16.3%(P=0.0156)。
- 低基线MRI炎症患者中,阿巴西普联合MTX组与MTX组SDAI缓解率无显著差异(39.7% vs 32.3%,P=0.4961)。
关键数值与推荐
- SDAI缓解定义为≤3.3,CDAI缓解定义为≤2.8,DAS28-CRP缓解定义为<2.6,并评估Boolean缓解。
- 基线MRI炎症分组基于既往开发的单侧手腕增强MRI滑膜炎和骨炎截断值。
临床怎么用
- 对早期血清阳性MTX未治RA患者,可用基线手腕增强MRI评估客观炎症水平以辅助识别预后不良者。
- 基线MRI高炎症者可能从阿巴西普联合MTX初始治疗中获更高缓解率,低炎症者联合治疗未见显著额外获益。
局限性
- 本分析为AVERT研究的事后分析。
- 仅纳入有MRI结果的患者,未报告具体样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: High magnetic resonance imaging (MRI)-detected inflammation is associated with greater progression and poorer outcomes in rheumatoid arthritis (RA). This analysis aimed to determine if baseline MRI inflammation was related to clinical response and remission in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study. METHODS: AVERT was a phase IIIb, randomized, controlled trial with a 12-month, double-blind treatment period enrolling patients with early (≤2 years' duration), anti-citrullinated peptide-positive methotrexate (MTX)-naive RA. In this post hoc analysis, patients in the abatacept plus MTX (n = 114) and MTX (n = 111) arms with available MRI results were stratified into low and high baseline MRI inflammation groups based on previously developed cutoffs of synovitis and osteitis on unilateral hand-wrist contrast-enhanced MRI. Simplified Disease Activity Index (SDAI) remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity Score in 28 joints using the C-reactive protein level (<2.6) were assessed. RESULTS: Overall, 100 of 225 patients (44.4%) had high baseline MRI inflammation. In patients with high baseline MRI inflammation, a significantly greater proportion achieved remission at 12 months with abatacept plus MTX versus MTX across SDAI (45.1% versus 16.3%; P = 0.0022), CDAI (47.1% versus 20.4%; P = 0.0065), and Boolean indices (39.2% versus 16.3%; P = 0.0156). In patients with low baseline MRI inflammation, remission rates were not significantly different with abatacept plus MTX versus MTX (SDAI: 39.7% versus 32.3%; P = 0.4961). CONCLUSION: In seropositive, MTX-naive patients with early RA and presence of objectively measured high inflammation by MRI, indicating poor prognosis, remission rates were higher with abatacept plus MTX treatment versus MTX.
引用
- Ahmad HA, Baker JF, Østergaard M, et al. Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis. Arthritis Care Res (Hoboken). 2020. PMID: 31549793. doi:10.1002/acr.24072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。